View Older Stories View More Recent Stories

Mar 15, 2021 06:46AM Gilead (GILD), Merck (MRK) Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Mar 15, 2021 06:45AM Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Mar 9, 2021 01:24PM Gilead Sciences (GILD) Lenacapavir Demonstrates Sustained Long-Acting Efficacy
Mar 9, 2021 01:22PM Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
Mar 8, 2021 06:29AM Gilead (GILD) Says Biktarvy Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
Mar 8, 2021 06:28AM Gilead Sciences (GILD) Announces U.S. FDA Approves Yescarta for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
Mar 6, 2021 07:01AM Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
Mar 5, 2021 07:49PM U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
Mar 4, 2021 08:44AM Gilead Sciences (GILD) Completes Acquisition of MYR GmbH
Mar 4, 2021 08:39AM Gilead Sciences Completes Acquisition of MYR GmbH
Mar 2, 2021 05:21PM  Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs
Feb 18, 2021 08:01AM Gilead Sciences to Present at Upcoming Investor Conferences
Feb 16, 2021 10:30AM Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach
Feb 10, 2021 05:15PM Gilead's (GILD) Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
Feb 10, 2021 05:15PM Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
Feb 8, 2021 08:00AM Kite Appoints Frank Neumann as Worldwide Head of Clinical Development
Feb 4, 2021 04:02PM Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend
Jan 21, 2021 04:01PM Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
Jan 19, 2021 08:00AM Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
Jan 12, 2021 08:05AM Gilead (GILD) and Vir Biotechnology (VIR) Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
Jan 12, 2021 08:00AM Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
Jan 11, 2021 09:23AM Pre-Open Stock Movers 01/11: (MESO) (LLY) (WBAI) Higher; (MARA) (RIOT) (MSTR) Lower (more...)
Dec 21, 2020 04:01PM Gilead Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
Dec 16, 2020 06:14AM Gilead's (GILD) Kite Tecartus Granted Conditional Marketing Authorization for Treatment of R/R Mantle Cell Lymphoma in Europe
Dec 16, 2020 03:01AM Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe
Dec 10, 2020 04:48PM Gilead (GILD) Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy in Metastatic TNBC
Dec 10, 2020 04:48PM Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer
Dec 9, 2020 11:00AM Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States
Dec 8, 2020 04:11PM Gilead Sciences (GILD) Announces Jeffrey A. Bluestone to Board
Dec 8, 2020 04:05PM Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors
Dec 7, 2020 06:35AM Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
Dec 7, 2020 06:35AM Gilead's (GILD) Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
Dec 6, 2020 03:00PM Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
Dec 6, 2020 12:30PM Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
Dec 5, 2020 12:30PM Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study
Dec 5, 2020 10:00AM New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma
Dec 5, 2020 10:00AM New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
Nov 23, 2020 07:00PM Gilead Sciences to Present at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020
Nov 18, 2020 08:35AM Gilead Sciences' (GILD) Lenacapavir Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV
Nov 18, 2020 08:35AM Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV
Nov 15, 2020 05:30PM Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
Nov 5, 2020 09:00AM Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020
Oct 28, 2020 04:02PM Gilead Sciences Announces Fourth Quarter 2020 Dividend
Oct 23, 2020 09:15AM Gilead Sciences (GILD) Completes Acquisition of Immunomedics (IMMU)
Oct 23, 2020 09:15AM Gilead Sciences Completes Acquisition of Immunomedics, Inc.
Oct 22, 2020 04:09PM Gilead Sciences (GILD) Confirms FDA Approved its Antiviral Veklury for Treatment of COVID-19
Oct 22, 2020 04:02PM U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
Oct 22, 2020 12:23PM Gilead Sciences (GILD) Announces Anthony Welters to Board
Oct 22, 2020 12:15PM Anthony Welters Joins Gilead Sciences’ Board of Directors
Oct 21, 2020 07:05AM Gilead Sciences (GILD) Presents New Data Showing Biktarvy Effective for the Treatment of HIV in Black Americans
View More Recent Stories View Older Stories